IDO1 and neoplasm: Our data similarly support the concept of blocking IDO in combination with gamma radiation or olaparib (alone and in together, and potentially with additional targeting of BRCA2 in an induced lethality strategy) or cisplatin, with the critical new information that IDO can potentiate the action of these treatment modalities independent of immune function and regardless of the capacity of endogenous immune cells to recognize and kill tumor cells.